Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors

TW202641857APending Publication Date: 2026-10-16AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114150475
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-12-20
Filing Date
2020-12-21
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080781_001
    Figure TWG2TA001080781_001
  • Figure TWG2TA001080781_002
    Figure TWG2TA001080781_002
  • Figure TWG2TA001080781_003
    Figure TWG2TA001080781_003
Patent Text Reader

Abstract

The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
Need to check novelty before this filing date? Find Prior Art